Risk factors for mpox infection among MSM with STIs in northern Taiwan, 2022–2024

IF 1.5 4区医学 Q3 INFECTIOUS DISEASES

Journal of Infection and Chemotherapy Pub Date : 2025-06-10 DOI:10.1016/j.jiac.2025.102750

Wei-Yen Chen , Shu-Hsing Cheng , Cheng-Pin Chen , Shu-Yuan Lee , Shin-Yen Ku , Shu-Ting Gan , Chen-En Hsieh , Chien-Yu Cheng

{"title":"Risk factors for mpox infection among MSM with STIs in northern Taiwan, 2022–2024","authors":"Wei-Yen Chen , Shu-Hsing Cheng , Cheng-Pin Chen , Shu-Yuan Lee , Shin-Yen Ku , Shu-Ting Gan , Chen-En Hsieh , Chien-Yu Cheng","doi":"10.1016/j.jiac.2025.102750","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Since 2022, Mpox has emerged among men who have sex with men (MSM) in Taiwan. Data on local risk factors remain limited, particularly the role of sexual behavior and STI history.</div></div><div><h3>Methods</h3><div>We conducted a retrospective case–control study at a regional hospital in Taoyuan from 2022 to 2024. MSM aged ≥18 years with at least one STI were included. Mpox cases were compared to STI-only controls. Data on demographics, HIV status, and behaviors were analyzed using Firth logistic regression.</div></div><div><h3>Results</h3><div>Among 729 MSM, 42 had confirmed Mpox. Having more than two prior STIs was strongly associated with Mpox (aOR = 17.32; 95 % CI: 5.64–53.17). In contrast, HIV viral load >1000 copies/mL (aOR = 0.02) and multiple sexual partners (aOR = 0.22) were linked to lower odds of infection.</div></div><div><h3>Conclusions</h3><div>Multiple STIs were a strong predictor of Mpox. Lower infection rates among viremic or sexually active individuals may reflect behavior change or healthcare engagement. STI history may help guide targeted Mpox prevention.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 8","pages":"Article 102750"},"PeriodicalIF":1.5000,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1341321X25001473","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Since 2022, Mpox has emerged among men who have sex with men (MSM) in Taiwan. Data on local risk factors remain limited, particularly the role of sexual behavior and STI history.

Methods

We conducted a retrospective case–control study at a regional hospital in Taoyuan from 2022 to 2024. MSM aged ≥18 years with at least one STI were included. Mpox cases were compared to STI-only controls. Data on demographics, HIV status, and behaviors were analyzed using Firth logistic regression.

Results

Among 729 MSM, 42 had confirmed Mpox. Having more than two prior STIs was strongly associated with Mpox (aOR = 17.32; 95 % CI: 5.64–53.17). In contrast, HIV viral load >1000 copies/mL (aOR = 0.02) and multiple sexual partners (aOR = 0.22) were linked to lower odds of infection.

Conclusions

Multiple STIs were a strong predictor of Mpox. Lower infection rates among viremic or sexually active individuals may reflect behavior change or healthcare engagement. STI history may help guide targeted Mpox prevention.

查看原文本刊更多论文

台湾北部地区男男性传播感染人群m痘感染危险因素分析(2022-2024

自2022年以来，台湾男男性行为者（MSM）中出现了m痘。关于当地风险因素的数据仍然有限，特别是性行为和性传播感染史的作用。方法于2022 ~ 2024年在桃园某地区医院进行回顾性病例对照研究。年龄≥18岁且至少有一次性传播感染的男男性行为者被纳入其中。将m痘病例与单纯性传播感染对照进行比较。使用Firth逻辑回归分析人口统计学、HIV状态和行为数据。结果729例男男性接触者中，确诊m痘42例。既往有两次以上性传播感染与m痘密切相关(aOR = 17.32；95% ci: 5.64-53.17)。相比之下，HIV病毒载量>；1000拷贝/mL （aOR = 0.02）和多个性伴侣（aOR = 0.22）与较低的感染几率有关。结论多发性传播感染是m痘的重要预测因素。病毒血症或性活跃个体的感染率较低可能反映了行为改变或保健参与。性传播感染史可能有助于指导有针对性的m痘预防。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection and Chemotherapy INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY

CiteScore

4.10

自引率

4.50%

发文量

303

审稿时长

47 days

期刊介绍： The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.